<?xml version="1.0" encoding="utf-8" standalone="no"?>
<billStatus>
  <version>3.0.0</version>
  <bill>
    <number>666</number>
    <updateDate>2023-01-15T23:03:28Z</updateDate>
    <updateDateIncludingText>2023-01-15T23:03:28Z</updateDateIncludingText>
    <originChamber>Senate</originChamber>
    <originChamberCode>S</originChamberCode>
    <type>S</type>
    <introducedDate>2003-03-19</introducedDate>
    <congress>108</congress>
    <committees>
      <item>
        <systemCode>ssju00</systemCode>
        <name>Judiciary Committee</name>
        <chamber>Senate</chamber>
        <type>Standing</type>
        <activities>
          <item>
            <name>Hearings by</name>
            <date>2004-10-06T19:16:25Z</date>
          </item>
        </activities>
      </item>
      <item>
        <systemCode>ssfi00</systemCode>
        <name>Finance Committee</name>
        <chamber>Senate</chamber>
        <type>Standing</type>
        <activities>
          <item>
            <name>Referred to</name>
            <date>2003-03-20T02:00:09Z</date>
          </item>
        </activities>
      </item>
    </committees>
    <actions>
      <item>
        <actionDate>2004-10-06</actionDate>
        <committees>
          <item>
            <systemCode>ssju00</systemCode>
            <name>Judiciary Committee</name>
          </item>
        </committees>
        <sourceSystem>
          <name>Senate</name>
        </sourceSystem>
        <text>Committees on Health, Education, Labor, and Pensions; the Judiciary. Hearings held.</text>
        <type>Committee</type>
      </item>
      <item>
        <actionDate>2003-03-19</actionDate>
        <committees>
          <item>
            <systemCode>ssfi00</systemCode>
            <name>Finance Committee</name>
          </item>
        </committees>
        <sourceSystem>
          <name>Senate</name>
        </sourceSystem>
        <text>Read twice and referred to the Committee on Finance.</text>
        <type>IntroReferral</type>
      </item>
      <item>
        <actionDate>2003-03-19</actionDate>
        <text>Sponsor introductory remarks on measure. (CR S4009-4017)</text>
        <type>IntroReferral</type>
        <actionCode>B00100</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2003-03-19</actionDate>
        <text>Introduced in Senate</text>
        <type>IntroReferral</type>
        <actionCode>10000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
    </actions>
    <sponsors>
      <item>
        <bioguideId>L000304</bioguideId>
        <fullName>Sen. Lieberman, Joseph I. [D-CT]</fullName>
        <firstName>JOSEPH</firstName>
        <lastName>LIEBERMAN</lastName>
        <party>D</party>
        <state>CT</state>
        <middleName>I.</middleName>
        <isByRequest>N</isByRequest>
      </item>
    </sponsors>
    <cosponsors>
      <item>
        <bioguideId>H000338</bioguideId>
        <fullName>Sen. Hatch, Orrin G. [R-UT]</fullName>
        <firstName>ORRIN</firstName>
        <lastName>HATCH</lastName>
        <party>R</party>
        <state>UT</state>
        <middleName>GRANT</middleName>
        <sponsorshipDate>2003-03-19</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
    </cosponsors>
    <policyArea>
      <name>Health</name>
    </policyArea>
    <subjects>
      <legislativeSubjects>
        <item>
          <name>Administrative procedure</name>
        </item>
        <item>
          <name>Animal diseases</name>
        </item>
        <item>
          <name>Animals</name>
        </item>
        <item>
          <name>Antibiotics</name>
        </item>
        <item>
          <name>Antitrust law</name>
        </item>
        <item>
          <name>Armed Forces and National Security</name>
        </item>
        <item>
          <name>Arsenic</name>
        </item>
        <item>
          <name>Biochemistry</name>
        </item>
        <item>
          <name>Biological warfare</name>
        </item>
        <item>
          <name>Biotechnology</name>
        </item>
        <item>
          <name>Blood diseases</name>
        </item>
        <item>
          <name>Business records</name>
        </item>
        <item>
          <name>Capital investments</name>
        </item>
        <item>
          <name>Cardiovascular diseases</name>
        </item>
        <item>
          <name>Chemical warfare</name>
        </item>
        <item>
          <name>Cholera</name>
        </item>
        <item>
          <name>Civil Rights and Liberties, Minority Issues</name>
        </item>
        <item>
          <name>Clinical trials</name>
        </item>
        <item>
          <name>Colleges</name>
        </item>
        <item>
          <name>Commerce</name>
        </item>
        <item>
          <name>Communicable diseases</name>
        </item>
        <item>
          <name>Conferences</name>
        </item>
        <item>
          <name>Confidential communications</name>
        </item>
        <item>
          <name>Congress</name>
        </item>
        <item>
          <name>Congressional oversight</name>
        </item>
        <item>
          <name>Congressional reporting requirements</name>
        </item>
        <item>
          <name>Corporation taxes</name>
        </item>
        <item>
          <name>Department of Health and Human Services</name>
        </item>
        <item>
          <name>Diseases</name>
        </item>
        <item>
          <name>Drug approvals</name>
        </item>
        <item>
          <name>Drug industry</name>
        </item>
        <item>
          <name>Drugs</name>
        </item>
        <item>
          <name>EBB Terrorism</name>
        </item>
        <item>
          <name>Economics and Public Finance</name>
        </item>
        <item>
          <name>Emergency Management</name>
        </item>
        <item>
          <name>Environmentally induced diseases</name>
        </item>
        <item>
          <name>Epidemics</name>
        </item>
        <item>
          <name>Equipment and supplies</name>
        </item>
        <item>
          <name>Federal aid to education</name>
        </item>
        <item>
          <name>Federal aid to health facilities</name>
        </item>
        <item>
          <name>Federal aid to research</name>
        </item>
        <item>
          <name>Federal-state relations</name>
        </item>
        <item>
          <name>Finance and Financial Sector</name>
        </item>
        <item>
          <name>Genetics</name>
        </item>
        <item>
          <name>Government Operations and Politics</name>
        </item>
        <item>
          <name>Government procurement</name>
        </item>
        <item>
          <name>Government trust funds</name>
        </item>
        <item>
          <name>Governmental investigations</name>
        </item>
        <item>
          <name>Grants-in-aid</name>
        </item>
        <item>
          <name>Heavy metals</name>
        </item>
        <item>
          <name>Higher education</name>
        </item>
        <item>
          <name>Hospitals</name>
        </item>
        <item>
          <name>Immunology and vaccination</name>
        </item>
        <item>
          <name>Income tax</name>
        </item>
        <item>
          <name>Indemnity</name>
        </item>
        <item>
          <name>Industrial buildings</name>
        </item>
        <item>
          <name>Industrial management</name>
        </item>
        <item>
          <name>Intellectual property</name>
        </item>
        <item>
          <name>International Affairs</name>
        </item>
        <item>
          <name>International cooperation</name>
        </item>
        <item>
          <name>Investment tax credit</name>
        </item>
        <item>
          <name>Laboratories</name>
        </item>
        <item>
          <name>Laboratory animals</name>
        </item>
        <item>
          <name>Law</name>
        </item>
        <item>
          <name>Lead</name>
        </item>
        <item>
          <name>Liability (Law)</name>
        </item>
        <item>
          <name>License agreements</name>
        </item>
        <item>
          <name>Malaria</name>
        </item>
        <item>
          <name>Medical innovations</name>
        </item>
        <item>
          <name>Medical screening</name>
        </item>
        <item>
          <name>Medical statistics</name>
        </item>
        <item>
          <name>Medical supplies</name>
        </item>
        <item>
          <name>Medical technology</name>
        </item>
        <item>
          <name>Medical tests</name>
        </item>
        <item>
          <name>Mercury</name>
        </item>
        <item>
          <name>Microbiology</name>
        </item>
        <item>
          <name>Nervous system diseases</name>
        </item>
        <item>
          <name>Nonprofit organizations</name>
        </item>
        <item>
          <name>Nosocomial infections</name>
        </item>
        <item>
          <name>Nuclear terrorism</name>
        </item>
        <item>
          <name>Orphan drugs</name>
        </item>
        <item>
          <name>Partnerships</name>
        </item>
        <item>
          <name>Patents</name>
        </item>
        <item>
          <name>Pharmaceutical research</name>
        </item>
        <item>
          <name>Plague</name>
        </item>
        <item>
          <name>Public Lands and Natural Resources</name>
        </item>
        <item>
          <name>Quality control</name>
        </item>
        <item>
          <name>Radiation</name>
        </item>
        <item>
          <name>Radiation safety</name>
        </item>
        <item>
          <name>Radioactive pollution</name>
        </item>
        <item>
          <name>Research and development</name>
        </item>
        <item>
          <name>Research and development tax credit</name>
        </item>
        <item>
          <name>Respiratory diseases</name>
        </item>
        <item>
          <name>Right of privacy</name>
        </item>
        <item>
          <name>Salmonella</name>
        </item>
        <item>
          <name>Science, Technology, Communications</name>
        </item>
        <item>
          <name>Security measures</name>
        </item>
        <item>
          <name>Skin diseases</name>
        </item>
        <item>
          <name>Social Welfare</name>
        </item>
        <item>
          <name>Tax credits</name>
        </item>
        <item>
          <name>Tax exclusion</name>
        </item>
        <item>
          <name>Tax incentives</name>
        </item>
        <item>
          <name>Taxation</name>
        </item>
        <item>
          <name>Technological innovations</name>
        </item>
        <item>
          <name>Technology transfer</name>
        </item>
        <item>
          <name>Terrorism</name>
        </item>
        <item>
          <name>Typhoid fever</name>
        </item>
        <item>
          <name>Vaccination</name>
        </item>
        <item>
          <name>Vaccines</name>
        </item>
        <item>
          <name>Victims of terrorism</name>
        </item>
        <item>
          <name>Virus diseases</name>
        </item>
        <item>
          <name>Weapons of mass destruction</name>
        </item>
        <item>
          <name>Yellow fever</name>
        </item>
        <item>
          <name>Zoning and zoning law</name>
        </item>
      </legislativeSubjects>
      <policyArea>
        <name>Health</name>
      </policyArea>
    </subjects>
    <summaries>
      <summary>
        <versionCode>00</versionCode>
        <actionDate>2003-03-19</actionDate>
        <actionDesc>Introduced in Senate</actionDesc>
        <updateDate>2006-11-28T17:35:40Z</updateDate>
        <text><![CDATA[Biological, Chemical, and Radiological Weapons Countermeasures Research Act - Amends the Homeland Security Act of 2002 to add a new title, Title 18: Biological, Chemical, and Radiological Countermeasures Research, which may be cited as the Biological, Chemical, and Radiological Weapons Countermeasures Research Act of 2003.<p>Directs the Secretary of Homeland Security to make available to manufacturers of terror weapons countermeasures, and to publish, a list of materials that may be used as weapons of mass destruction (WMD). Directs the Secretary to revise the list on at least an annual basis. Requires the Secretary to determine countermeasures that diagnose, treat, or prevent infection from biological agents or toxins (countermeasures) for each item on the list.<p>Requires private sector entities that are engaged in certain research to register with the  Department of Homeland Security if they wish to benefit from various tax, patent, procurement, liability limitations, and other incentives established under this Act. Classifies such research as: (1) countermeasures; (2) equipment to detect a terrorist attack carried out with a terror weapon (detection equipment); (3) diagnostics to detect, identify, or analyze biological agents or toxins (diagnostics); and (4) research tools used in the laboratory (research tools) that enable the rapid and effective development of countermeasures.<p>Establishes in the Treasury of the United States a "Terror Weapon Countermeasure Purchase Fund (TWCPF)" to purchase, and provide adequate payment for, countermeasures, detection equipment, diagnostics, and research tools.<p>Extends market exclusivity for new drugs that are countermeasures.<p>Authorizes the Director of the National Institutes of Health (NIH) to award partnership challenge grants to promote joint ventures between NIH, its grantees, and for-profit biotechnology, pharmaceutical, and medical device industries for the development of countermeasures and research tools.]]></text>
      </summary>
    </summaries>
    <title>Biological, Chemical, and Radiological Weapons Countermeasures Research Act</title>
    <titles>
      <item>
        <titleType>Display Title</titleType>
        <title>Biological, Chemical, and Radiological Weapons Countermeasures Research Act</title>
      </item>
      <item>
        <titleType>Official Title as Introduced</titleType>
        <title>A bill to provide incentives to increase research by private sector entities to develop antivirals, antibiotics and other drugs, vaccines, microbicides, detection, and diagnostic technologies to prevent and treat illnesses associated with a biological, chemical, or radiological weapons attack.</title>
        <billTextVersionName>Introduced in Senate</billTextVersionName>
        <billTextVersionCode>IS</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Titles as Introduced</titleType>
        <title>Biological, Chemical, and Radiological Weapons Countermeasures Research Act</title>
      </item>
      <item>
        <titleType>Short Titles as Introduced for portions of this bill</titleType>
        <title>Biological, Chemical, and Radiological Weapons Countermeasures Research Act of 2003</title>
      </item>
    </titles>
    <textVersions>
      <item>
        <type>Introduced in Senate</type>
        <date>2003-03-19T05:00:00Z</date>
        <formats/>
      </item>
    </textVersions>
    <latestAction>
      <actionDate>2004-10-06</actionDate>
      <text>Committees on Health, Education, Labor, and Pensions; the Judiciary. Hearings held.</text>
    </latestAction>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>
